- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03976713
Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD
Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD: A Randomized, Double-blind, Placebo Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
COPD is a highly prevalent disease, with a prevalence among people 40 years of age or older of 10.1% worldwide and 13.7% in China. COPD has become the third leading cause of death worldwide. Frequent acute exacerbation and exercise limitation broadly exist in COPD patients, especially those in GOLD stage 3 or 4. Although appropriate pharmacological therapies have been proven to be effective in COPD management, however, many gaps are still to be filled. For example, the adverse effects of pharmacologic therapies can never be ignored. The investigator's previous studies suggested that traditional Chinese medicine (TCM) has effect on GOLD stage 3 or 4 COPD.
This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect of Bufei Yishen granule on reducing acute exacerbation in GOLD stage 3 or 4 COPD subjects. After a 14-day run-in period, 348 subjects will be randomly assigned to treatment group or control group for 52-week treatment. The primary outcomes are frequency and duration of acute exacerbation. The secondary outcomes include mortality, pulmonary function, clinical symptoms, exercise capacity, quality of life and treatment satisfaction. Safety will also be assessed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Xueqing Yu, Doctor
- Phone Number: 86-371-66248624
- Email: yxqshi@163.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
-
Contact:
- Xueqing Yu, Doctor
- Phone Number: 86-371-66248624
- Email: yxqshi@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A confirmed diagnosis of GOLD stage 3 or 4 COPD.
- Syndrome differentiation meets criteria of Qi deficiency of the lung and spleen syndrome, Qi deficiency of the lung and kidney syndrome or Qi and Yin deficiency of the lung and kidney syndrome.
- Age ranges from 40 years to 80 years.
- With informed consent signed.
Exclusion Criteria:
- Pregnant and lactating women.
- Patients with severe cardiovascular and cerebrovascular diseases.
- Patients with severe liver and kidney diseases.
- Patients with asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism, chronic respiratory failure or other severe respiratory diseases.
- Patients with tumor after resection, radiotherapy or chemotherapy in the past 5 years.
- Patients with severe neuromuscular disorders, severe arthritis or severe peripheral vascular diseases.
- Patients with severe cognitive and psychiatric disorders.
- Patients with diabetes.
- Patients who were administered oral glucocorticoids in the past 4 weeks.
- Patients who have participated in other clinical studies in the past 4 weeks.
- People who are allergic to the treatment drugs.
- Patients who have experienced one or more acute exacerbation in the past 4 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bufei Yishen granule plus Western medicine
Patients in this arm will receive Bufei Yishen granule in addition to Western medicine.
|
Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
|
Placebo Comparator: Placebo Bufei Yishen granule plus Western medicine
Patients in this arm will receive placebo Bufei Yishen granule in addition to Western medicine.
|
Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule.
The appearance, weight, color and odor of the preparation are the same as those of treatment group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of acute exacerbation
Time Frame: Up to week 52.
|
Frequency of acute exacerbation will be recorded.
|
Up to week 52.
|
Duration of acute exacerbation
Time Frame: Up to week 52.
|
Duration of acute exacerbation will be recorded.
|
Up to week 52.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: Up to week 52.
|
The mortality will be calculated.
|
Up to week 52.
|
FEV1
Time Frame: Change from baseline FEV1 at week 26 and 52.
|
Forced expiratory volume in one second ( FEV1) will be used to assess pulmonary function.
|
Change from baseline FEV1 at week 26 and 52.
|
Clinical symptom assessment questionnaire
Time Frame: Change from baseline clinical symptom assessment questionnaire scores at week 13, 26, 39 and 52.
|
Clinical symptom assessment questionnaire of COPD will be used to assess symptom.
|
Change from baseline clinical symptom assessment questionnaire scores at week 13, 26, 39 and 52.
|
6MWD
Time Frame: Change from baseline 6MWD at week 13, 26, 39 and 52.
|
Six-minute walk distance (6MWD) will be conducted to assess exercise capacity
|
Change from baseline 6MWD at week 13, 26, 39 and 52.
|
CAT
Time Frame: Change from baseline CAT scores at week 13, 26, 39 and 52.
|
COPD assessment test (CAT) will be used to assess quality of life.
|
Change from baseline CAT scores at week 13, 26, 39 and 52.
|
SF-36
Time Frame: Change from baseline SF-36 scores at week 13, 26, 39 and 52.
|
The MOS 36-Item Short-Form Health Survey (SF-36) will be used to assess quality of life.
|
Change from baseline SF-36 scores at week 13, 26, 39 and 52.
|
mCOPD-PRO
Time Frame: Change from baseline mCOPD-PRO scores at week 13, 26, 39 and 52.
|
The modified COPD patient-reported outcome scale (mCOPD-PRO) will be used to assess quality of life.
The mCOPD-PRO contains 27 items in three domains.
mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status.
|
Change from baseline mCOPD-PRO scores at week 13, 26, 39 and 52.
|
mESQ-COPD
Time Frame: Change from baseline mESQ-COPD scores at week 13, 26, 39 and 52.
|
The modified effectiveness satisfaction questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction.
The mESQ-COPD contains 19 items in four domains.
mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction.
|
Change from baseline mESQ-COPD scores at week 13, 26, 39 and 52.
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Anticonvulsants
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Tiotropium Bromide
- Bromides
Other Study ID Numbers
- TCM for GOLD stage 3 or 4 COPD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Guy's and St Thomas' NHS Foundation TrustSuspendedChronic Obstructive Pulmonary Disease SevereUnited Kingdom
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (13645005)United States
Clinical Trials on Bufei Yishen granule
-
Henan University of Traditional Chinese MedicineThe First Affiliated Hospital of Henan University of Traditional Chinese... and other collaboratorsNot yet recruitingChronic Obstructive Pulmonary Disease
-
Henan University of Traditional Chinese MedicineUnknown
-
Henan University of Traditional Chinese MedicineJiangsu Province Hospital of Traditional Chinese MedicineUnknownChronic Obstructive Pulmonary DiseaseChina
-
Dongfang Hospital Beijing University of Chinese...UnknownCognitive ImpairmentChina
-
Henan University of Traditional Chinese MedicineUnknownPulmonary Disease, Chronic Obstructive
-
Korea Health Industry Development InstituteUnknown
-
Shanghai University of Traditional Chinese MedicineLonghua HospitalRecruiting
-
Xiyuan Hospital of China Academy of Chinese Medical...The First Affiliated Hospital of Henan University of Traditional Chinese... and other collaboratorsRecruitingNon-erosive Reflux Disease | Diarrhea-Predominant Irritable Bowel SyndromeChina
-
Xiyuan Hospital of China Academy of Chinese Medical...First Affiliated Hospital of Heilongjiang Chinese Medicine University; Liuzhou... and other collaboratorsRecruitingGastroesophageal Reflux | Functional DysphoniaChina
-
Tasly Pharmaceutical Group Co., LtdUnknownIrritable Bowel Syndrome With DiarrheaChina